<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553306</url>
  </required_header>
  <id_info>
    <org_study_id>2179.00</org_study_id>
    <secondary_id>NCI-2010-01281</secondary_id>
    <nct_id>NCT00553306</nct_id>
  </id_info>
  <brief_title>Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back&#xD;
      into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different&#xD;
      ways and stop tumor cells from growing. Giving laboratory-treated T cells together with&#xD;
      aldesleukin after cyclophosphamide may be an effective treatment for melanoma.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving laboratory-treated T&#xD;
      cells together with aldesleukin after cyclophosphamide and to see how well they work in&#xD;
      treating patients with stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and toxicity of cellular adoptive immunotherapy in melanoma patients&#xD;
      using autologous CD4+ and CD8+ antigen-specific T cell clones.&#xD;
&#xD;
      II. To evaluate the antitumor effects of CD4+ and CD8+ antigen-specific T cells in patients&#xD;
      with metastatic melanoma.&#xD;
&#xD;
      III. To determine the duration of in vivo persistence of adoptively transferred CD8+&#xD;
      antigen-specific T cell clones in the presence or absence of transferred CD4+ T cells.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the in vivo antitumor efficacy of the infused autologous antigen-specific CD4+ T&#xD;
      cells.&#xD;
&#xD;
      OUTLINE: This is a phase I study followed by a phase II study.&#xD;
&#xD;
      Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients&#xD;
      then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2&#xD;
      hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13.&#xD;
      Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up weekly for 8 weeks, and then&#xD;
      periodically thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toxicity as assessed by NCI CTC version 3.0</measure>
    <time_frame>8 weeks post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor effects of CD4+ and CD8+ antigen-specific T-cells</measure>
    <time_frame>8 weeks post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of in vivo persistence of adoptively transferred CD8+ antigen-specific T cell clones in the presence or absence of transferred CD4+ T cells</measure>
    <time_frame>8 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo antitumor efficacy of the infused autologous antigen-specific CD4+ T cells</measure>
    <time_frame>8 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>AL</other_name>
    <other_name>Autologous Lymphocytes</other_name>
    <other_name>autologous T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>interleukin II</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
    <other_name>TCGF, interleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
    <other_name>Enduxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Histopathologically documented metastatic melanoma&#xD;
&#xD;
          -  Karnofsky Performance status of at least 70%&#xD;
&#xD;
          -  Expected survival of greater than 16 weeks&#xD;
&#xD;
          -  WBC &gt; 2,500/uL (ANC &gt; 1,000 uL)&#xD;
&#xD;
          -  Platelet count &gt; 80,000 uL&#xD;
&#xD;
          -  HCT &gt; 28%&#xD;
&#xD;
          -  Patients whose tumor expresses targeted antigen and restricting allele against which&#xD;
             CD4 and CD8 T cell clones can be generated&#xD;
&#xD;
          -  No CNS metastasis&#xD;
&#xD;
          -  Patient's whose tumor expresses an antigen and HLA type for which both an HLA Class I&#xD;
             and HLA Class II epitope are listed, will be eligible for this study&#xD;
&#xD;
          -  CD4 and CD8 T cell clones do not necessarily have to target the same antigen to be&#xD;
             eligible for the study, it is only necessary that the targeted antigen is expressed by&#xD;
             the tumor and its epitope is restricted by an HLA allele expressed by the patient&#xD;
&#xD;
          -  Evidence of measurable residual disease by clinical exam or imaging studies&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Current central nervous system metastases; patients with history of CNS metastases&#xD;
             that show no current evidence of active disease are eligible&#xD;
&#xD;
          -  Patients with active infections or oral temperature &gt; 38.2 C within 72 hours of study&#xD;
             entry or systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
          -  Current treatment with steroids&#xD;
&#xD;
          -  Patients who are HIV seropositive (poor CD4 T cell generation due to low CD4 T cell&#xD;
             recovery and likely HIV reservoir in stimulator cells used in vitro culture)&#xD;
&#xD;
          -  Prognosis less than 6 months&#xD;
&#xD;
          -  FOR T CELL INFUSION:&#xD;
&#xD;
          -  Pregnant women, nursing mothers of reproductive ability who are unwilling to use&#xD;
             effective contraception or abstinence; women of childbearing potential must have a&#xD;
             negative pregnancy test within two weeks prior to entry&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Significant hepatic dysfunction (hepatic toxicity &gt;= grade 2 (NCICTC) of whatever&#xD;
             origin&#xD;
&#xD;
          -  Clinically significant pulmonary dysfunction, as determined by medical history and&#xD;
             physical exam; patients so identified will undergo pulmonary functions testing and&#xD;
             those with FEV1 &lt; 60% of normal or DLco (corr for Hgb) &lt; 55% will be excluded&#xD;
&#xD;
          -  Significant cardiovascular abnormalities as defined by any one of the following:&#xD;
             congestive heart failure, clinically significant hypotension, symptoms of coronary&#xD;
             artery disease, presence of cardiac arrhythmias on EKG requiring drug therapy&#xD;
&#xD;
          -  Ejection fraction &lt; 50% excludes patients&#xD;
&#xD;
          -  Current central nervous system metastases; patients with history of CNS metastases&#xD;
             that show no current evidence of active disease are eligible&#xD;
&#xD;
          -  Serum calcium &gt; 12 mg/dL&#xD;
&#xD;
          -  Chemotherapeutic agents (standard or experimental), radiation therapy, or other&#xD;
             immunosuppressive therapies less than 4 weeks prior to T cell therapy; patients with&#xD;
             bulky disease may undergo 1-2 courses of cytoreductive chemotherapy but treatment will&#xD;
             be discontinued at least 4 weeks prior to T cell therapy; patients should have&#xD;
             recovered fully from all previous treatment-related toxicities&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Patients must not be receiving any other experimental drugs within 4 weeks of the&#xD;
             initiation of the protocol and must have recovered from all side effects of such&#xD;
             therapy&#xD;
&#xD;
          -  Patients with &gt;= Grade 2 hepatotoxicity are excluded&#xD;
&#xD;
          -  Patients with a history of autoimmune disease requiring active systemic therapy are&#xD;
             excluded&#xD;
&#xD;
          -  The following agents are not allowed while on study: systemic corticosteroids (except&#xD;
             as outlined for management of toxicity of nontransduced CTL), immunotherapy (for&#xD;
             example, interleukins, interferons, melanoma vaccines, intravenous immunoglobulin,&#xD;
             expanded polyclonal TIL or LAK therapy), pentoxifylline, or other investigational&#xD;
             agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2007</study_first_posted>
  <disposition_first_submitted>February 13, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 13, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 15, 2017</disposition_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

